Table 5.
Results of each study and pooled estimations of recurrence of ascites, hepatic encephalopathy, severe hepatic encephalopathy, gastrointestinal bleeding and hepatorenal syndrome by sensitivity analysis
| Ref. |
Liver-transplantation |
Liver-disease-related mortality |
Non-liver-disease-related mortality |
Recurrence ascites |
HE |
Severe HE |
Hepatorenal syndrome |
||||||||||||||
| TIPS | Para | OR (95%CI) | TIPS | Para | OR (95%CI) | TIPS | Para | OR (95%CI) | TIPS | Para | OR (95%CI) | TIPS | Para | OR (95%CI) | TIPS | Para | OR (95%CI) | TIPS | Para | OR (95%CI) | |
| Lebrec et al[10] | 0/13 | 1/12 | 0.28 (0.01-7.67) | 41438 | 4/12 | 1.71 (0.34-8.68) | 3/13 | 0/12 | 8.33 (0.39-180.36) | 10/13 | 11/12 | 0.30 (0.03-3.41) | 3/13 | 0/12 | 8.33 (0.39-180.36) | 2/13 | 0/12 | 5.43 (0.24-125.59) | - | - | - |
| Rössle et al[9] | 0 | 2/31 | 0.52 (0.04-6.04) | 10/29 | 20/31 | 0.29 (0.10-0.84) | 5/29 | 3/31 | 1.94 (0.42-8.99) | 14/29 | 26/31 | 0.18 (0.05-0.60) | 6/29 | 3/31 | 2.43 (0.55-10.82) | - | - | - | - | - | - |
| Ginés et al[8] | 7/35 | 7/35 | 1.00 (0.31-3.23) | - | - | - | - | - | - | 17/35 | 29/35 | 0.20 (0.06-0.59) | 27/35 | 23/35 | 1.76 (0.61-5.05) | 21/35 | 12/35 | 2.88 (1.09-7.60) | 3/35 | 11/35 | 0.20 (0.05-0.81) |
| Sanyal et al[11] | 16/52 | 17/57 | 1.05 (0.46-2.37) | 13/52 | 13/57 | 1.13 (0.47-2.72) | 5/52 | 6/57 | 0.90 (0.26-3.16) | 22/52 | 48/57 | 0.14 (0.06-0.34) | 22/52 | 13/57 | 2.48 (1.08-5.68) | 15/52 | 10/57 | 1.91 (0.77-4.73) | - | - | - |
| Salerno et al[12] | 4/33 | 4/33 | 1.00 (0.23-4.39) | 10/33 | 16/33 | 0.46 (0.17-1.27) | 3/33 | 4/33 | 0.72 (0.15-3.53) | 13/33 | 32/33 | 0.02 (0.00-0.17) | 20/33 | 13/33 | 2.37 (0.88-6.35) | 14/33 | 10/33 | 1.69 (0.61-4.67) | 3/33 | 5/33 | 0.56 (0.12-2.56) |
| Narahara et al[13] | 0/30 | 0/30 | - | 8/30 | 13/30 | 0.48 (0.16-1.41) | 9/30 | 8/30 | 1.18 (0.38-3.63) | 22/30 | 27/30 | 0.31 (0.07-1.29) | 20/30 | 5/30 | 10.00 (2.94-34.01) | - | - | - | - | - | - |
| Total | 28/192 | 31/198 | 0.94 (0.53-1.67) | 47/157 | 66/163 | 0.62 (0.39-0.98)a | 25/157 | 21/163 | 1.27 (0.68-2.38) | 98/192 | 173/198 | 0.15 (0.09-0.24)b | 98/192 | 57/198 | 2.95 (1.87-4.66)b | 52/133 | 32/137 | 2.18 (1.27-3.76)b | 6/68 | 16/68 | 0.32 (0.12-0.86)a |
| Subgroup without the study by Lebrec et al, 1996 | 28/179 | 30/186 | 0.98 (0.54-1.77) | 41/144 | 62/151 | 0.56 (0.34-0.91)a | 22/144 | 21/151 | 1.11 (0.57-2.14) | 88/179 | 162/186 | 0.14 (0.08-0.24)b | 95/179 | 57/186 | 2.86 (1.80-4.54)b | 50/120 | 32/125 | 2.10 (1.21-3.67)b | - | - | - |
a
P < 0.05,
b
P < 0.01; No significant heterogeneity was observed among these meta-analyses (I2 = 0%-31%). All of these meta-analyses were performed under the fixed-effect model. TIPS: Transjugular intrahepatic portosystemic shunt; Para: Paracentesis; HE: Hepatic encephalopathy.